Seeking Alpha: Cellectar Biosciences Partners with Florida Cancer Specialists & Research Institute to Support the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting Cellectar Biosciences Partners with Florida Cancer Specialists & Research Institute to Support the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting Business Insider: Cellectar Biosciences’ Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom’s Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression ... Cellectar Biosciences’ Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom’s Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression ... Nasdaq: Cellectar Biosciences Pursues Conditional EMA Approval for Iopofosine I 131 in Waldenstrom Macroglobulinemia Following Positive Phase 2 Trial Results Cellectar Biosciences, Inc.
announced its intention to seek conditional approval from the European Medicines Agency (EMA) for its drug iopofosine I 131 to treat Waldenstrom Macroglobulinemia, ... Cellectar Biosciences Pursues Conditional EMA Approval for Iopofosine I 131 in Waldenstrom Macroglobulinemia Following Positive Phase 2 Trial Results Nasdaq: Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)
